We orchestrate the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.

Affini-T’s co-founders have proven expertise in innovation for immune cell therapies, and our experienced management team is committed to advancing breakthrough therapies for patients. Our validated T cell therapy-enabling platforms leverage high-throughput screening, synthetic biology and gene editing technologies, allowing our team to overcome key hurdles in cellular engineering that have prevented the field from developing therapies for solid tumor cancers in the past.

Affini-T is developing specific TCR-based immunotherapies for solid tumors using 2 complementary therapeutic modalities: Autologous TCR-T cell therapies and bispecific T Cell Engagers.

• Our validated TCR-T cell therapy-enabling platforms leverage high-throughput screening, synthetic biology and gene editing technologies, allowing our team to overcome key hurdles in cellular engineering that have prevented the field from developing therapies for solid tumor cancers in the past.
• Our bispecific T Cell Engager platform leverages bispecific T Cell Engager formats to redirect endogenous T cells against tumor cells.

Utilizing a multi-pronged approach designed to safely and precisely target oncogenic driver mutations, we strike at the core of tumor biology. We deploy a significant toolkit of technologies to outsmart the immunosuppressive tumor microenvironment and generate a sustained anti-tumor response.

We endeavor to remove barriers in drug production, scalability, and treatment accessibility, developing patient centric immune cell therapies to address even the most hard-to-treat cancers.

Leadership

Driven by science and innovation. Focused on patients. Our world-class team is comprised of the pioneers who have shown success across the cell therapy and T Cell Engager landscape and beyond.

Investors